Guajacuran

Guajacuran is a pharmaceutical product that contains the active ingredient guaifenesin, supplied in an intravenous formulation and marketed in the European Union. It belongs to the expectorant class and is used to facilitate the clearance of mucus from the respiratory tract. The product is intended for healthcare professional administration in clinical settings.

Guajacuran is indicated for conditions where thinning and clearance of respiratory secretions are desired. It is commonly employed in the following situations:

- Relief of cough with productive sputum - Management of bronchitis‑related mucus accumulation - Adjunct therapy for respiratory tract congestion - Supportive treatment of acute upper respiratory infections - Use during exacerbations of chronic obstructive pulmonary disease (COPD) when mucus clearance is needed

Side effects of Guajacuran may vary in frequency and severity. The most frequently reported events are generally mild, while serious reactions are uncommon but require prompt medical attention.

Common: - Nausea - Headache - Dizziness - Injection‑site pain or irritation - Mild skin rash

Serious: - Anaphylactic or severe allergic reaction - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Significant hypotension or other hemodynamic changes - Rare cases of pulmonary edema

Before prescribing Guajacuran, clinicians should consider several safety aspects to minimize risk. Important precautions include: - Assess for known hypersensitivity to guaifenesin or any excipients - Use cautiously in patients with cardiovascular instability or severe hypertension - Monitor fluid balance in individuals prone to fluid overload - Evaluate renal and hepatic function, as impairment may affect drug clearance - Avoid use in patients with uncontrolled asthma exacerbations without appropriate bronchodilator therapy - Document pregnancy status; safety data are limited

Guajacuran may interact with other medicines, altering its efficacy or safety profile. Interaction guidance is grouped for clarity.

Avoid: - Concurrent use with other potent expectorants or mucolytics that could cause excessive airway irritation - Co‑administration with drugs known to cause severe hypotension (e.g., potent vasodilators)

Use with caution: - Antihistamines or sedatives that may increase dizziness or drowsiness - Diuretics, which could exacerbate fluid‑balance changes - Bronchodilators, to ensure coordinated management of airway resistance - Other intravenous solutions, to avoid incompatibility or precipitation